540 related articles for article (PubMed ID: 22834834)
1. Polymeric nanomedicines as a promising vehicle for solid tumor therapy and targeting.
Gupta M; Agrawal GP; Vyas SP
Curr Mol Med; 2013 Jan; 13(1):179-204. PubMed ID: 22834834
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. Extravasation of polymeric nanomedicines across tumor vasculature.
Danquah MK; Zhang XA; Mahato RI
Adv Drug Deliv Rev; 2011 Jul; 63(8):623-39. PubMed ID: 21144874
[TBL] [Abstract][Full Text] [Related]
4. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
Muthu MS; Singh S
Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
[TBL] [Abstract][Full Text] [Related]
5. [Advances in the study of tumor pH-responsive polymeric micelles for cancer drug targeting delivery].
Xu JX; Tang JB; Zhao LH; Shen YQ
Yao Xue Xue Bao; 2009 Dec; 44(12):1328-35. PubMed ID: 21351464
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting toxicity and efficacy of polymeric nanomedicines.
Igarashi E
Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
[TBL] [Abstract][Full Text] [Related]
7. Polymeric vesicles: from drug carriers to nanoreactors and artificial organelles.
Tanner P; Baumann P; Enea R; Onaca O; Palivan C; Meier W
Acc Chem Res; 2011 Oct; 44(10):1039-49. PubMed ID: 21608994
[TBL] [Abstract][Full Text] [Related]
8. Polymer-based stimuli-responsive nanosystems for biomedical applications.
Joglekar M; Trewyn BG
Biotechnol J; 2013 Aug; 8(8):931-45. PubMed ID: 23843342
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors.
Danhier F; Danhier P; De Saedeleer CJ; Fruytier AC; Schleich N; des Rieux A; Sonveaux P; Gallez B; Préat V
Int J Pharm; 2015 Feb; 479(2):399-407. PubMed ID: 25578367
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
Frazier N; Ghandehari H
Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
[TBL] [Abstract][Full Text] [Related]
11. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.
Rahman M; Akhter S; Ahmad J; Ahmad MZ; Beg S; Ahmad FJ
Expert Opin Drug Deliv; 2015 Apr; 12(4):635-52. PubMed ID: 25439967
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment.
Jain V; Jain S; Mahajan SC
Curr Drug Deliv; 2015; 12(2):177-91. PubMed ID: 25146439
[TBL] [Abstract][Full Text] [Related]
14. Stimuli-responsive polymersomes for cancer therapy.
Thambi T; Park JH; Lee DS
Biomater Sci; 2016 Jan; 4(1):55-69. PubMed ID: 26456625
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine: novel approaches in human and veterinary therapeutics.
Irache JM; Esparza I; Gamazo C; Agüeros M; Espuelas S
Vet Parasitol; 2011 Aug; 180(1-2):47-71. PubMed ID: 21680101
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
Kwon S; Ko H; You DG; Kataoka K; Park JH
Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
[TBL] [Abstract][Full Text] [Related]
17. What nanomedicine in the clinic right now really forms nanoparticles?
Svenson S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2014; 6(2):125-35. PubMed ID: 24415653
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
19. Design and development of polymer conjugates as anti-angiogenic agents.
Segal E; Satchi-Fainaro R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
[TBL] [Abstract][Full Text] [Related]
20. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
